Express News | C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China

BenzingaNov 6 07:06 ET

Additional Considerations Required While Assessing Betta Pharmaceuticals' (SZSE:300558) Strong Earnings

Simply Wall StAug 12 18:39 ET

Betta Pharmaceuticals Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Simply Wall StAug 7 18:38 ET

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Simply Wall StAug 2 20:06 ET

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Simply Wall StJul 12 02:53 ET

Is The Market Rewarding Betta Pharmaceuticals Co., Ltd. (SZSE:300558) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

Simply Wall StJun 19 03:48 ET